On November 12, 2021 Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, reported that new data from its best-in-class memory natural killer (NK) cell therapy platform at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 36th Annual Meeting (Press release, Wugen, NOV 12, 2021, View Source [SID1234595347]). The presentation highlighted the preclinical development and proprietary manufacturing details of Wugen’s lead product candidate WU-NK-101 for the treatment of relapsed/refractory (r/r) acute myeloid leukemia (AML). The findings presented at SITC (Free SITC Whitepaper) support development of WU-NK-101 as an off-the-shelf therapy for r/r AML and solid tumor indications.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"These data showcase our differentiated approach to off-the-shelf cell therapies for cancer," said Dan Kemp, Ph.D., President and Chief Executive Officer of Wugen. "Our memory NK cell platform is uniquely designed to overcome the limitations of existing cell therapy alternatives by delivering enhanced function, persistence, and ultimately efficacy without the need for feeder cells during the manufacturing process. Eliminating this step simplifies the process and allows us to deliver a safer product. We have prioritized manufacturing from the start and are proud that today’s data underscores our preparedness to deliver our product at-scale and provide powerful treatments to patients."
Today’s presentation highlighted the following:
WU-NK-101 memory NK cells demonstrated robust cytotoxic efficacy in vitro, producing high levels of immune-activating cytokines and immune-attracting chemokines.
WU-NK-101 showed strong anti-tumor activity in vivo, with long-term persistence and increased CD16 expression.
WU-NK-101 drove robust antibody-dependent cell-mediated cytotoxicity (ADCC) activity against solid tumor cell lines in combination with approved therapeutic antibodies.
Wugen’s process enables commercial-scale manufacturing of WU-NK-101 by using WU-PRIME, a single GMP-grade fusion protein complex, and WU-EXPAND, a feeder cell-free expansion system, in combination with a proprietary cryopreservation method to maintain an enhanced memory phenotype and preserve functionality.
The details of Wugen’s presentation at SITC (Free SITC Whitepaper) are as follows:
Title: Development of WU-NK-101, a feeder cell-free expanded allogeneic memory NK cell product with potent anti-tumor activity
Presenting Author: Mary E. Mathyer, Ph.D.
Abstract Number: 188
Abstracts will be available Tuesday, November 9, 2021, at 8:00 a.m. ET
Additional meeting information can be found on the SITC (Free SITC Whitepaper) website at:
The poster will be available on the "Scientific Publications" section of Wugen’s website.